The FDA will finish September with three action dates and one of the year’s most highly-anticipated advisory committee meetings.
Posts
Despite concerns regarding neffy’s lack of clinical evidence, the panel of experts voted in favor of the nasal spray’s approval for the emergency treatment of type 1 allergic reactions.
The FDA is kicking off May with three target action dates and three advisory committee meetings, including one for a high-profile investigational gene therapy.
